Investors in Aurinia Pharmaceuticals Inc. AUPH need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $20 Put had some of the highest implied...
Aurinia has been under the spotlight recently due to significant restructuring efforts.
KEVIN TANG, a director at $AUPH ($AUPH), bought 300,000 shares of the company on 12-05-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings...
As the new week unfolds, earnings and economic data will again dictate sentiment.
Aurinia plans to slash 45% of its entire workforce with an aim to save more than $40 million in annual operating expenses.
The biotech's premium valuation doesn't seem to be sitting well with investors.
The biotech's board is exploring strategic alternatives to boost shareholder value.
September S&P 500 futures (ESU23) are trending up +0.33% this morning as market participants awaited a reading on the Federal Reserve’s preferred inflation gauge.